Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Corporate Information (Details Textual)

v3.24.2.u1
Note 1 - Corporate Information (Details Textual)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
USD ($)
$ / shares
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
$ / shares
Jun. 30, 2023
USD ($)
Aug. 07, 2024
$ / shares
Mar. 27, 2024
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
Jul. 18, 2023
May 31, 2013
Reduction in Workforce, Percentage               70.00%  
Reduction in Workforce, Cost             $ 7,500    
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares $ 0.001   $ 0.001       $ 0.001    
Cash, Cash Equivalents, and Short-Term Investments $ 19,700   $ 19,700            
Net Income (Loss) Attributable to Parent (3,590) $ 3,976 (8,482) $ (9,207)          
Retained Earnings (Accumulated Deficit) $ (323,446)   $ (323,446)       $ (314,964)    
Subsequent Event [Member] | Series F Preferred Stock [Member]                  
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares         $ 0.01        
Preferred Stock, Voting Rights, Number of Votes Per Share         25,000,000        
Subsequent Event [Member] | Series F Preferred Stock [Member] | Board of Directors Chairman [Member]                  
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares         $ 0.001        
Shares Issued, Price Per Share (in dollars per share) | $ / shares         $ 1        
B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Phase 2 Trials [Member]                  
Contracts Receivable, Claims and Uncertain Amounts           $ 15,000      
B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Pivotal Clinical Trials [Member]                  
Contracts Receivable, Claims and Uncertain Amounts           $ 40,000      
Pieris Pharmaceuticals GmbH [Member]                  
Business Acquisition, Percentage of Voting Interests Acquired                 100.00%